Home > Research > Publications & Outputs > Potential of trans fats policies to reduce soci...

Links

Text available via DOI:

View graph of relations

Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. / Allen, Kirk Christopher; Pearson-Stuttard, Jonathan ; Hooton, William et al.
In: BMJ, Vol. 2015, 351, 15.09.2015.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Allen KC, Pearson-Stuttard J, Hooton W, Diggle PJ, Capewell S, O'Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ. 2015 Sept 15;2015:351. doi: 10.1136/bmj.h4583

Author

Allen, Kirk Christopher ; Pearson-Stuttard, Jonathan ; Hooton, William et al. / Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England : cost effectiveness modelling study. In: BMJ. 2015 ; Vol. 2015.

Bibtex

@article{006f55cbe1404ca5b549f7e76b9ef9b2,
title = "Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study",
abstract = "Objectives To determine health and equity benefits and cost effectiveness of policies to reduce or eliminate trans fatty acids from processed foods, compared with consumption remaining at most recent levels in England.Design Epidemiological modelling study.Setting Data from National Diet and Nutrition Survey, Low Income Diet and Nutrition Survey, Office of National Statistics, and health economic data from other published studiesParticipants Adults aged ≥25, stratified by fifths of socioeconomic circumstance.Interventions Total ban on trans fatty acids in processed foods; improved labelling of trans fatty acids; bans on trans fatty acids in restaurants and takeaways.Main outcome measures Deaths from coronary heart disease prevented or postponed; life years gained; quality adjusted life years gained. Policy costs to government and industry; policy savings from reductions in direct healthcare, informal care, and productivity loss.Results A total ban on trans fatty acids in processed foods might prevent or postpone about 7200 deaths (2.6%) from coronary heart disease from 2015-20 and reduce inequality in mortality from coronary heart disease by about 3000 deaths (15%). Policies to improve labelling or simply remove trans fatty acids from restaurants/fast food could save between 1800 (0.7%) and 3500 (1.3%) deaths from coronary heart disease and reduce inequalities by 600 (3%) to 1500 (7%) deaths, thus making them at best half as effective. A total ban would have the greatest net cost savings of about £265m (€361m, $415m) excluding reformulation costs, or £64m if substantial reformulation costs are incurred outside the normal cycle.Conclusions A regulatory policy to eliminate trans fatty acids from processed foods in England would be the most effective and equitable policy option. Intermediate policies would also be beneficial. Simply continuing to rely on industry to voluntary reformulate products, however, could have negative health and economic outcomes.",
author = "Allen, {Kirk Christopher} and Jonathan Pearson-Stuttard and William Hooton and Diggle, {Peter John} and Simon Capewell and Martin O'Flaherty",
year = "2015",
month = sep,
day = "15",
doi = "10.1136/bmj.h4583",
language = "English",
volume = "2015",
journal = "BMJ",
issn = "0959-8138",
publisher = "British Medical Association",

}

RIS

TY - JOUR

T1 - Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England

T2 - cost effectiveness modelling study

AU - Allen, Kirk Christopher

AU - Pearson-Stuttard, Jonathan

AU - Hooton, William

AU - Diggle, Peter John

AU - Capewell, Simon

AU - O'Flaherty, Martin

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Objectives To determine health and equity benefits and cost effectiveness of policies to reduce or eliminate trans fatty acids from processed foods, compared with consumption remaining at most recent levels in England.Design Epidemiological modelling study.Setting Data from National Diet and Nutrition Survey, Low Income Diet and Nutrition Survey, Office of National Statistics, and health economic data from other published studiesParticipants Adults aged ≥25, stratified by fifths of socioeconomic circumstance.Interventions Total ban on trans fatty acids in processed foods; improved labelling of trans fatty acids; bans on trans fatty acids in restaurants and takeaways.Main outcome measures Deaths from coronary heart disease prevented or postponed; life years gained; quality adjusted life years gained. Policy costs to government and industry; policy savings from reductions in direct healthcare, informal care, and productivity loss.Results A total ban on trans fatty acids in processed foods might prevent or postpone about 7200 deaths (2.6%) from coronary heart disease from 2015-20 and reduce inequality in mortality from coronary heart disease by about 3000 deaths (15%). Policies to improve labelling or simply remove trans fatty acids from restaurants/fast food could save between 1800 (0.7%) and 3500 (1.3%) deaths from coronary heart disease and reduce inequalities by 600 (3%) to 1500 (7%) deaths, thus making them at best half as effective. A total ban would have the greatest net cost savings of about £265m (€361m, $415m) excluding reformulation costs, or £64m if substantial reformulation costs are incurred outside the normal cycle.Conclusions A regulatory policy to eliminate trans fatty acids from processed foods in England would be the most effective and equitable policy option. Intermediate policies would also be beneficial. Simply continuing to rely on industry to voluntary reformulate products, however, could have negative health and economic outcomes.

AB - Objectives To determine health and equity benefits and cost effectiveness of policies to reduce or eliminate trans fatty acids from processed foods, compared with consumption remaining at most recent levels in England.Design Epidemiological modelling study.Setting Data from National Diet and Nutrition Survey, Low Income Diet and Nutrition Survey, Office of National Statistics, and health economic data from other published studiesParticipants Adults aged ≥25, stratified by fifths of socioeconomic circumstance.Interventions Total ban on trans fatty acids in processed foods; improved labelling of trans fatty acids; bans on trans fatty acids in restaurants and takeaways.Main outcome measures Deaths from coronary heart disease prevented or postponed; life years gained; quality adjusted life years gained. Policy costs to government and industry; policy savings from reductions in direct healthcare, informal care, and productivity loss.Results A total ban on trans fatty acids in processed foods might prevent or postpone about 7200 deaths (2.6%) from coronary heart disease from 2015-20 and reduce inequality in mortality from coronary heart disease by about 3000 deaths (15%). Policies to improve labelling or simply remove trans fatty acids from restaurants/fast food could save between 1800 (0.7%) and 3500 (1.3%) deaths from coronary heart disease and reduce inequalities by 600 (3%) to 1500 (7%) deaths, thus making them at best half as effective. A total ban would have the greatest net cost savings of about £265m (€361m, $415m) excluding reformulation costs, or £64m if substantial reformulation costs are incurred outside the normal cycle.Conclusions A regulatory policy to eliminate trans fatty acids from processed foods in England would be the most effective and equitable policy option. Intermediate policies would also be beneficial. Simply continuing to rely on industry to voluntary reformulate products, however, could have negative health and economic outcomes.

U2 - 10.1136/bmj.h4583

DO - 10.1136/bmj.h4583

M3 - Journal article

VL - 2015

JO - BMJ

JF - BMJ

SN - 0959-8138

M1 - 351

ER -